Neoadjuvant Chemotherapy With PD-1 Inhibitors Combined With SIB-IMRT in the Treatment of Locally Advanced Rectal Cancer
Status:
Recruiting
Trial end date:
2026-08-31
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the efficacy and safety of tislelizumab combined with
simultaneous integrated boost intensity-modulated radiotherapy in treating locally advanced
rectal cancer. To explore a new PD-1 inhibitor adjuvant chemotherapy model combined with
radiotherapy to treat locally advanced rectal cancer.